Claims for Patent: 8,309,124

Summary for Patent: 8,309,124

Title:	Delayed release tablet with defined core geometry
Abstract:	A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
Inventor(s):	Vergnault; Guy (Kembs, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee:	Jagotec AG (Muttenz, CH)
Application Number:	13/424,069
Patent Claims:	1. A method of administering a glucocorticosteroid active substance selected from prednisone, prednisolone, and methylprednisolone to a patient in need thereof comprising administering to the patient a dosage form comprising a core and a coating surrounding the core, wherein the core comprises the glucocorticosteroid active substance and further comprises at least one disintegrating agent that, upon exposure to aqueous media, provides a force to rupture the coating, wherein the coating comprises at least one insoluble or poorly water soluble hydrophobic material such that the glucocorticosteroid active substance is released from the core as a result of the rupturing of the coating and not as a result of the glucocorticosteroid active substance diffusing through the coating, provided that the coating does not include an insoluble or poorly water soluble hydrophobic material that is a polymer, and wherein the coating ruptures upon immersion in an aqueous medium, regardless of pH of the aqueous medium, after a period of between about 2 to about 6 hours to release the glucocorticosteroid active substance, and provided that the dosage form does not comprise a further enteric coating. 2. The method according to claim 1, wherein the dosage form comprises 1 mg prednisone. 3. The method according to claim 1, wherein the dosage form comprises 5 mg prednisone. 4. The method according to claim 1, wherein the coating does not include a disintegrating agent. 5. The method according to claim 1, wherein the dosage form releases at least 80% of the glucocorticosteroid active substance after 4.5 hours. 6. The method according to claim 1, wherein the dosage form releases about 100% of the glucocorticosteroid active substance after 5 hours. 7. The method according to claim 1, wherein, in vivo, the release of the glucocorticosteroid active substance from the dosage form is independent of the effects of food. 8. A method of treating rheumatoid arthritis in a patient in need thereof comprising administering to the patient a dosage form comprising a core and a coating surrounding the core, wherein the core comprises the glucocorticosteroid active substance and further comprises at least one disintegrating agent that, upon exposure to aqueous media, provides a force to rupture the coating, wherein the coating comprises at least one insoluble or poorly water soluble hydrophobic material such that the glucocorticosteroid active substance is released from the core as a result of the rupturing of the coating and not as a result of the glucocorticosteroid active substance diffusing through the coating, provided that the coating does not include an insoluble or poorly water soluble hydrophobic material that is a polymer, and wherein the coating ruptures upon immersion in an aqueous medium, regardless of pH of the aqueous medium, after a period of between about 2 to about 6 hours to release the glucocorticosteroid active substance, and provided that the dosage form does not comprise a further enteric coating. 9. The method according to claim 8, wherein the dosage form comprises 1 mg prednisone. 10. The method according to claim 8, wherein the dosage form comprises 5 mg prednisone. 11. The method according to claim 8, wherein the coating does not include a disintegrating agent. 12. The method according to claim 8, wherein the dosage form releases at least 80% of the glucocorticosteroid active substance after 4.5 hours. 13. The method according to claim 8, wherein the dosage form releases about 100% of the glucocorticosteroid active substance after 5 hours. 14. The method according to claim 8, wherein, in vivo, the release of the glucocorticosteroid active substance from the dosage form is independent of the effects of food.